Cargando…

Evolution of antimicrobial resistance in E. coli biofilm treated with high doses of ciprofloxacin

The evolution of antimicrobial resistance (AMR) has mainly been studied in planktonic bacteria exposed to sub-inhibitory antimicrobial (AM) concentrations. However, in a number of infections that are treated with AMs the bacteria are located in biofilms where they tolerate high doses of AM. In the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Nesse, Live L., Osland, Ane Mohr, Asal, Basma, Mo, Solveig Sølverød
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509014/
https://www.ncbi.nlm.nih.gov/pubmed/37731931
http://dx.doi.org/10.3389/fmicb.2023.1246895
_version_ 1785107649238401024
author Nesse, Live L.
Osland, Ane Mohr
Asal, Basma
Mo, Solveig Sølverød
author_facet Nesse, Live L.
Osland, Ane Mohr
Asal, Basma
Mo, Solveig Sølverød
author_sort Nesse, Live L.
collection PubMed
description The evolution of antimicrobial resistance (AMR) has mainly been studied in planktonic bacteria exposed to sub-inhibitory antimicrobial (AM) concentrations. However, in a number of infections that are treated with AMs the bacteria are located in biofilms where they tolerate high doses of AM. In the present study, we continuously exposed biofilm residing E. coli at body temperature to high ciprofloxacin (CIP) concentrations increasing from 4 to 130 times the minimal inhibitory concentration (MIC), i.e., from 0.06 to 2.0 mg/L. After 1 week, the biofilms were full of CIP resistant bacteria. The evolutionary trajectory observed was the same as described in the literature for planktonic bacteria, i.e., starting with a single mutation in the target gene gyrA followed by mutations in parC, gyrB, and parE, as well as in genes for regulation of multidrug efflux pump systems and outer membrane porins. Strains with higher numbers of these mutations also displayed higher MIC values. Furthermore, the evolution of CIP resistance was more rapid, and resulted in strains with higher MIC values, when the bacteria were biofilm residing than when they were in a planktonic suspension. These results may indicate that extensive clinical AM treatment of biofilm-residing bacteria may not only fail to eradicate the infection but also pose an increased risk of AMR development.
format Online
Article
Text
id pubmed-10509014
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105090142023-09-20 Evolution of antimicrobial resistance in E. coli biofilm treated with high doses of ciprofloxacin Nesse, Live L. Osland, Ane Mohr Asal, Basma Mo, Solveig Sølverød Front Microbiol Microbiology The evolution of antimicrobial resistance (AMR) has mainly been studied in planktonic bacteria exposed to sub-inhibitory antimicrobial (AM) concentrations. However, in a number of infections that are treated with AMs the bacteria are located in biofilms where they tolerate high doses of AM. In the present study, we continuously exposed biofilm residing E. coli at body temperature to high ciprofloxacin (CIP) concentrations increasing from 4 to 130 times the minimal inhibitory concentration (MIC), i.e., from 0.06 to 2.0 mg/L. After 1 week, the biofilms were full of CIP resistant bacteria. The evolutionary trajectory observed was the same as described in the literature for planktonic bacteria, i.e., starting with a single mutation in the target gene gyrA followed by mutations in parC, gyrB, and parE, as well as in genes for regulation of multidrug efflux pump systems and outer membrane porins. Strains with higher numbers of these mutations also displayed higher MIC values. Furthermore, the evolution of CIP resistance was more rapid, and resulted in strains with higher MIC values, when the bacteria were biofilm residing than when they were in a planktonic suspension. These results may indicate that extensive clinical AM treatment of biofilm-residing bacteria may not only fail to eradicate the infection but also pose an increased risk of AMR development. Frontiers Media S.A. 2023-09-05 /pmc/articles/PMC10509014/ /pubmed/37731931 http://dx.doi.org/10.3389/fmicb.2023.1246895 Text en Copyright © 2023 Nesse, Osland, Asal and Mo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Nesse, Live L.
Osland, Ane Mohr
Asal, Basma
Mo, Solveig Sølverød
Evolution of antimicrobial resistance in E. coli biofilm treated with high doses of ciprofloxacin
title Evolution of antimicrobial resistance in E. coli biofilm treated with high doses of ciprofloxacin
title_full Evolution of antimicrobial resistance in E. coli biofilm treated with high doses of ciprofloxacin
title_fullStr Evolution of antimicrobial resistance in E. coli biofilm treated with high doses of ciprofloxacin
title_full_unstemmed Evolution of antimicrobial resistance in E. coli biofilm treated with high doses of ciprofloxacin
title_short Evolution of antimicrobial resistance in E. coli biofilm treated with high doses of ciprofloxacin
title_sort evolution of antimicrobial resistance in e. coli biofilm treated with high doses of ciprofloxacin
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509014/
https://www.ncbi.nlm.nih.gov/pubmed/37731931
http://dx.doi.org/10.3389/fmicb.2023.1246895
work_keys_str_mv AT nesselivel evolutionofantimicrobialresistanceinecolibiofilmtreatedwithhighdosesofciprofloxacin
AT oslandanemohr evolutionofantimicrobialresistanceinecolibiofilmtreatedwithhighdosesofciprofloxacin
AT asalbasma evolutionofantimicrobialresistanceinecolibiofilmtreatedwithhighdosesofciprofloxacin
AT mosolveigsølverød evolutionofantimicrobialresistanceinecolibiofilmtreatedwithhighdosesofciprofloxacin